With decades in gene therapy under his belt, Ronald Crystal launches new venture with up to 18 candidates in the pipe
Ronald Crystal began working in gene therapy in the 1980s, long before the first wave of approvals shook the industry. He took his ideas to Weill Cornell Medicine in 1993, where he helped build a large gene therapy program and spent more than a decade developing potential candidates.
Now, the gene therapy long hauler is launching his own company, Lexeo Therapeutics, with an $85 million Series A to drive three of the company’s AAV-administered candidates to market, it said Thursday. Crystal will take the role of chief scientific adviser with Pfizer veteran Nolan Townsend joining as CEO.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.